Race Oncology Limited is pleased to announce that Professor Borje Andersson has been appointed to the Board as a Non-Executive Director.
Prof Andersson is an internationally acclaimed leader in the fields of leukaemia and stem cell transplant research at MD Anderson Cancer Centre in Houston, Texas.
Prof Andersson was previously engaged as a scientific and clinical consultant to the Company (refer ASX announcement: 22 January 2019) and recently appointed Chair of RAC’s Clinical Advisory Board (refer ASX announcement: 5 December 2019).
Prof Andersson is the inventor of IV Busulfan, an FDA-approved drug used in stem cell transplantation.
Busulfan was approved in 1999 and has drastically improved survival for leukaemia patients, helping reduce the death rate in the first 100 days after transplant from 30-40% to less than 3%.
“Borje will make a tremendous addition to Race’s Board of Directors. He is a globally recognised research leader in the field of cancer drug development and has considerable experience with leading clinical trials through the FDA approval process,” said Race Oncology Chairman, Bill Garner.
Prof Andersson will be focused on the clinical strategy of both the Company’s planned Phase I/II paediatric AML trial and Phase II AML MRD trial. He will also advise on Race’s other clinical trial programs in Adult AML, Breast Cancer and Ovarian Cancer.
Prof Andersson’s network and expertise will greatly assist in expediting Race’s clinical trials, partnership initiatives and commercialisation activities.
“It is with the highest level of enthusiasm that I have accepted the offer of expanding my involvement with Race Oncology,” said Professor Andersson.
“I am eagerly looking forward to the Bisantrene trials in both acute leukaemia and solid tumours. These trials have the potential to demonstrate Bisantrene’s known excellent antitumor activity and lack of cardiac toxicity, and set a new standard for cancer treatment,” added Prof Andersson.